Persistent Systems Collaborates with NVIDIA on AI Drug Discovery
Filing Summary
Persistent Systems Limited has announced a collaboration with NVIDIA to develop AI-powered solutions for the Healthcare and Life Sciences industry. The partnership focuses on computational drug discovery using the NVIDIA BioNeMo Framework. Persistent will leverage NVIDIA’s AI Enterprise platform to create a Generative Molecules and Virtual Screening solution. This initiative aims to enhance molecular simulations and streamline drug discovery workflows. The collaboration will utilize NVIDIA’s infrastructure to support real-time scientific decision-making in regulated environments. Persistent continues to expand its AI capabilities through this strategic partnership.
Persistent Systems Limited has announced a collaboration with NVIDIA to develop AI-powered solutions for the Healthcare and Life Sciences (HLS) industry. The partnership focuses on advancing computational drug discovery using the NVIDIA BioNeMo Framework. Persistent aims to enhance research outcomes by integrating Generative AI and advanced analytics into its solutions.
The financial terms of the collaboration between Persistent Systems and NVIDIA have not been disclosed in the filing. The focus is on leveraging NVIDIA’s AI Enterprise platform to support specialized Life Sciences R&D use cases. This includes preclinical research and high-fidelity molecular simulation. The collaboration does not specify any payment structures or financial commitments.
The scope of the collaboration involves the development of a Generative Molecules and Virtual Screening (GenMolVS) solution. This solution is powered by the NVIDIA BioNeMo platform and NVIDIA NeMo Agent Toolkit. The GenMolVS solution will deliver AI-driven molecular simulations to model the physical and chemical properties of molecules. It aims to streamline real-time drug discovery workflows by enabling continuous decision-making across virtual screening and candidate prioritization. The solution supports the translation of digital simulations into informed wet laboratory experiments.
The collaboration is set against the backdrop of increasing pressure on HLS organizations to innovate within complex, regulated, and data-intensive environments. By combining Persistent’s domain expertise with NVIDIA’s AI platform, the partnership seeks to move Life Sciences enterprises from AI experimentation to real-world production deployments. This approach is intended to de-risk early-stage discovery and accelerate experimental cycles.
The timeline for the implementation of the collaboration’s initiatives has not been specified. However, Persistent plans to use NVIDIA Nemotron open models for further enhancement of its GenMolVS solution. The deployment of production-grade AI applications will utilize NVIDIA accelerated computes, servers, and microservices. These capabilities are designed to expedite the development of applications with cost-effective scaling options and accurate AI outputs embedded into enterprise workflows.
NVIDIA is a leader in AI computing and provides a comprehensive platform for AI-driven research and discovery. The company focuses on empowering industries with advanced AI solutions to meet global demands for innovation and efficiency.
Persistent Systems is a global services and solutions company specializing in AI-led, platform-driven Digital Engineering and Enterprise Modernization. The company is committed to innovation and client success, offering services in software engineering, data analytics, and cloud computing. Persistent is part of the MSCI India Index and is recognized for its commitment to sustainability and responsible business practices.